TrialBritish journal of clinical pharmacology2021

Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.

Antonia Davidson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.